

13. McKeon A, Lennon VA, Jacob A, MAtiello M, et al. Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis óptica. *Muscle Nerve*. 2009;39:87–90.
14. Wakayama Y. Aquaporin Expression in Normal and Pathological Skeletal Muscles: A Brief Review with Focus on AQP4. *Journal of Biomedicine and Biotechnology*. 2010;2010, 731569.
15. Chan KH, Kwan JS, Ho PW, Ho SL, Chui WH, Chu AC, et al. Aquaporin-4 water channel expression by thymoma of patients with and without myasthenia gravis. *J Neuroimmunol*. 2010;227(1-2):178–84.
16. Vaknin-Dembinsky A. Myasthenia Gravis—Associated Neuromyelitis Optica—Like Disease. *Archives of Neurology*. 2010;68(12):1557.

R. Piñar Morales^{a,*}, M. Todorova Petrova^b,
F.J. Barrero Hernández^a

^a Servicio de Neurología, Hospital Universitario Clínico San Cecilio, Granada, Spain

^b Servicio de Medicina Interna, Sección de Neurología, Hospital Punta Europa, Algeciras, Spain

* Corresponding author.

E-mail address: rpinarmorales@gmail.com

(R. Piñar Morales).

6 October 2019

<https://doi.org/10.1016/j.nrleng.2020.02.007>
2173-5808/

© 2020 Sociedad Española de Neurología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Comments on “Headache: pregnancy and breastfeeding. Recommendations of the Spanish Society of Neurology’s Headache Study Group”[☆]



Respecto al artículo «Cefalea: embarazo y lactancia. Recomendaciones del Grupo de Estudio de Cefaleas de la Sociedad Española de Neurología (GECSEN)»

Dear Editor:

We would like to comment on 2 relevant aspects of the article “Headache: pregnancy and breastfeeding. Recommendations of the Spanish Society of Neurology’s Headache Study Group,” published online in April 2019.¹ Firstly, we wish to mention the notice issued by the Spanish Agency for Medicines and Medical Devices on 12 September 2019,² which warned about a slight increase in the risk of orofacial clefts in children of women exposed to ondansetron during the first trimester of pregnancy. This drug should therefore be avoided in pregnant women, especially during the first trimester; pregnant women should be informed about these potential adverse effects, and effective contraceptive measures should be implemented when necessary.³

We would also like to stress the fact that no drug is exempt from risks, particularly in this population group; we should therefore be cautious and aim to avoid pharmacological treatment in these patients whenever possible. If pharmacological treatment is unavoidable, drugs should be selected in order of their safety, according to the safety data available, and patients must be duly informed about the associated risks. Lastly, any suspected adverse reaction must

be reported through the appropriate pharmacovigilance systems.

References

1. González-García N, Díaz de Terán J, López-Veloso AC, Mas-Sala N, Mínguez-Olaondo A, Ruiz-Piñero M, et al. Cefalea: embarazo y lactancia Recomendaciones del Grupo de Estudio de Cefaleas de la Sociedad Española de Neurología (GECSEN). *Neurología*. 2019. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S021348531930009X>
2. AEMPS. Ondansetrón: riesgo de defectos de cierre orofaciales (labio leporino, paladar hendido) tras su uso durante el primer trimestre del embarazo. Available from: <https://www.aemps.gob.es/informa/circulares/medicamentosveterinarios/seguridad-4/ondansetron-riesgo-de-defectos-de-cierre-orofaciales-labio-leporino-paladar-hendido-tras-su-uso-durante-el-primer-trimestre-del-embarazo/>
3. Zambelli-Weiner A, Via C, Yuen M, Weiner DJ, Kirby RS. First trimester ondansetron exposure and risk of structural birth defects. *Reprod Toxicol*. 2019;83:14–20. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0890623818301230>

N. Gonzalez-García^{a,*}, P. Pozo-Rosich^{b,c}

^a Unidad de Cefaleas, Hospital Clínico San Carlos, Madrid, Spain

^b Unidad de Cefalea, Servicio de Neurología, Hospital Universitari Vall d’Hebron, Barcelona, Spain

^c Grupo de Investigación en Cefalea, Vall d’Hebron Research Institute (VHIR), Universitat Autònoma Barcelona, Barcelona, Spain

* Corresponding author.

E-mail address: nurigongar@gmail.com

(N. Gonzalez-García).

<https://doi.org/10.1016/j.nrleng.2020.01.004>
2173-5808/

© 2020 Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Neurología. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

[☆] Please cite this article as: Gonzalez-García N, Pozo-Rosich P. Respecto al artículo «Cefalea: embarazo y lactancia. Recomendaciones del Grupo de Estudio de Cefaleas de la Sociedad Española de Neurología (GECSEN)». *Neurología*. 2021;36:176.